Faeth Therapeutics (FTH) Interest Coverage Ratio (2020 - 2025)
Faeth Therapeutics' (FTH) quarterly Interest Coverage Ratio came in at 1652.33 in Q4 2025, down 239.49% on a YoY basis from 1184.53 in Q4 2024, and down 104.37% quarter-over-quarter from 808.5 in Q3 2025.
Powered by 
Analysis
Faeth Therapeutics (FTH) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Faeth Therapeutics (FTH) has reported Interest Coverage Ratio for 6 consecutive years, with 1652.33 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Interest Coverage Ratio fell 239.49% year-over-year to 1652.33; the trailing twelve-month figure through Dec 2025 stood at 696.5 (down 92.2% YoY), and the FY2025 full-year result was 696.5, down 92.2% from the prior year.
- Interest Coverage Ratio retreated to 1652.33 in Q4 2025 per FTH's latest filing, from 808.5 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 63.34 in Q4 2022 and bottomed at 2656.33 in Q1 2021.
- Historically, Interest Coverage Ratio has averaged 515.49 across 5 years, with a median of 289.8 in 2023.
- The sharpest annual moves came in 2021 and 2022: Interest Coverage Ratio slumped 105363.49% in 2021, then jumped 305.91% in 2022.
- Over 5 years, Interest Coverage Ratio stood at 30.76 in 2021, then surged by 305.91% to 63.34 in 2022, then slumped by 514.66% to 262.65 in 2023, then plunged by 85.31% to 486.71 in 2024, then sank by 239.49% to 1652.33 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1652.33, 808.5, and 520.6 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Faeth Therapeutics | 218.99 Mn | 218.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1,652.33 |
| Sep 30, 2025 | -808.50 |
| Jun 30, 2025 | -520.60 |
| Mar 31, 2025 | -559.54 |
| Dec 31, 2024 | -486.71 |
| Sep 30, 2024 | -372.52 |
| Jun 30, 2024 | -324.46 |
| Mar 31, 2024 | -311.79 |
| Dec 31, 2023 | -262.65 |
| Sep 30, 2023 | -234.45 |
| Jun 30, 2023 | -267.82 |
| Mar 31, 2023 | -262.10 |
| Dec 31, 2022 | 63.34 |
| Sep 30, 2022 | -1,394.10 |
| Jun 30, 2022 | -62.28 |
| Mar 31, 2022 | -51.39 |
| Dec 31, 2021 | -30.76 |
| Sep 30, 2021 | -48.21 |
| Jun 30, 2021 | -66.56 |
| Mar 31, 2021 | -2,656.33 |